DarioHealth Corp. (DRIO): Entry into a Material Definitive Agreement
DarioHealth Corp. (DRIO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-10.1 4 tm2621105d1_ex10-1.htm EXHIBIT 10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “ Agreement ”) is dated as of July 22, 2026, between DarioHealth Corp., a Delaware corporation (the “ Company ”), and the purchasers identified on the
How this was made
The 30-second read
Why it matters
A new securities purchase agreement typically implies DRIO will issue shares or common stock equivalents to purchasers, which can affect liquidity, dilution, and near-term valuation until the exact terms are reviewed.
Market read
This is a fresh, primary-source disclosure of a financing agreement, which can drive trading as investors price dilution and funding runway.
What to watch
Traders should focus on the agreement’s actual purchase size, pricing mechanism, any caps/floors, and whether proceeds fund specific milestones that reduce future financing needs.
Background
The 8-K reports Item 1.01, entry into a material definitive agreement, and includes an exhibit labeled a Securities Purchase Agreement.
Ticker impact
DarioHealth entered a material definitive securities purchase agreement, signaling a new capital raise/financing structure disclosed in the 8-K exhibit.
Near-term downside risk from dilution expectations, with volatility around deal terms as investors digest the financing mechanics.
The article is an SEC 8-K entry into a material definitive agreement, but the provided excerpt does not include the final dollar amount, pricing, or share issuance details needed for a precise impact estimate.
Market effects
Adds to the broader read-through that small-cap healthcare tech issuers may be actively using equity financing to fund operations.
Primarily US-listed small-cap sentiment; limited direct regional spillover implied.
Low global relevance beyond investor appetite for US micro/small-cap growth financings.
Counterpoint
If the financing is structured with favorable terms (e.g., limited dilution, strong investor demand), the market reaction could be muted or even positive once pricing details are known.
Key entities
- issuerDarioHealth Corp.
Company filing the 8-K and entering the securities purchase agreement.
- counterpartiesPurchasers (unnamed in excerpt)
Investors identified on the signature pages to the securities purchase agreement.
